What type of study is this?

December 8, 2025BloodOpen Access

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals survival outcomes improve with venetoclax in primary plasma cell leukemia, highlighting critical clinical features.

Median overall survival after first relapse in primary plasma cell leukemia is 39 months, indicating significant functional decline.
Patients with symptomatic relapses after initial therapy experience significantly shorter time to next treatment, at 3.9 months.
Observational analysis of clinical features revealed that past treatment lines greatly affect outcomes of subsequent therapies.
Findings suggest that novel agent-based treatments and autologous stem cell transplantation as first-line therapy do not prevent disease progression.

Kumar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals survival outcomes improve with venetoclax in primary plasma cell leukemia, highlighting critical clinical features.

Median overall survival after first relapse in primary plasma cell leukemia is 39 months, indicating significant functional decline.
Patients with symptomatic relapses after initial therapy experience significantly shorter time to next treatment, at 3.9 months.
Observational analysis of clinical features revealed that past treatment lines greatly affect outcomes of subsequent therapies.
Findings suggest that novel agent-based treatments and autologous stem cell transplantation as first-line therapy do not prevent disease progression.

Kumar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark